BSX Boston Scientific
Q1 2025 10-Q
Filed: May 1, 2025Period ending Mar 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Boston Scientific (BSX) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ1 2025 10-Q
Risk Factors
- • New insider trading risk: EVP Joseph F. Fitzgerald terminated May 23, 2024 Rule 10b5-1 plan, started new plan on Feb 27, 2025 for 306,372 shares sales
- • Most impactful legal risk: compliance with Rule 10b5-1(c) trading plans to avoid insider trading violations, including mandatory cooling-off periods
Quarterly Financial SummaryXBRL
Revenue
$4.7B
▲ +20.9% YoY
Net Income
$674M
▲ +36.2% YoY
Gross Margin
68.8%
▲ +17bp YoY
Operating Margin
19.8%
▲ +225bp YoY
Net Margin
14.5%
▲ +162bp YoY
EPS (Diluted)
$0.45
▲ +36.4% YoY
Operating Cash Flow
$541M
▲ +229.9% YoY
Source: XBRL data from Boston Scientific Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Boston Scientific Quarterly Reports
Get deeper insights on Boston Scientific
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.